Pay in 4 interest-free payments of $5.73 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Urban population growth and dietary shifts are increasing obesity prevalence rates, creating expanding demand for medical weight management interventions
However, treatments are typically FSA and HSA eligible, providing 20-30% savings through pre-tax dollars
What the research says: evidence summary Human trials show consistent but modest signals that fermentable fibers, resistant starch and protein-rich meals increase GLP-1 and reduce short-term energy intake in controlled settings
Semaglutide is a single GLP-1 agonist, while Retatrutide activates GLP-1, GIP, and glucagon receptors
Last year, Novo Nordisk announced it will spend over $8 billion to expand manufacturing sites in France and Denmark to boost production of drugs in its chronic illness portfolio, which includes Ozempic and Wegovy
US$ 29.93
US$ 20.08
US$ 27.07
